Studies that report survival rates and rates of clinical control (ie, normalised or improved BP, tapering of antihypertensive medication), biochemical control (ie, normalised renin and potassium), cardiovascular and cerebrovascular events (heart failure, myocardial infarction, stroke), as well as data on quality of life or renal function will be included. This evidence concerns the gene REN and stroke disorder.